Smith+Nephew Introduces RENASYS EDGE Negative Pressure Wound Therapy System

Smith+Nephew has launched its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the United States as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,¹ it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities.¹
 
The estimated annual financial burden of chronic wounds in the United States is $33 billion² and the condition affects some 8.2 million people.*3 The RENASYS EDGE System is designed for patients suffering from these wounds and living at home. Chronic wounds, including ulcers, have a huge impact on a patient’s life beyond just the pain and discomfort, with 68% often becoming self-conscious of their wound and many becoming isolated.⁴ The need to carry a bulky, noisy medical device that draws attention to their condition only increases this discomfort.
 
Smith+Nephew is also announcing two new national distribution partners for the RENASYS EDGE System—SunMED Medical Solutions and First Nation Group. These new partnerships will enable Smith+Nephew to introduce this technology to more patients on a national level and support its growing negative pressure wound therapy business. 
 
“When designing the RENASYS EDGE System we kept patients and their needs in the forefront of our minds. It’s the very definition of our purpose – Life Unlimited – allowing patients to continue with their daily lives while receiving prescribed negative pressure wound therapy,” stated Laura Ackerman, vice president and general manager, NPWT at Smith+Nephew. “And now with SunMED in the commercial healthcare market and First Nation Group supporting our veterans, RENASYS EDGE will be able to create an  impact on the way patients experience the benefit of negative pressure wound therapy in the comfort of their home.”
 
Burt Thomas, a RENASYS EDGE patient explained his experience with the system by stating, “I was not hindered by it at all. I was able to go on outings, play games, and was actually able to do a lot of day-to-day activities. I hope other people can benefit like I did.”  
 
For clinicians, the RENASYS EDGE system is intuitive and easy-to-use.⁵ Its user-friendly interface gives step-by-step guidance on therapy application,⁵ and technical support is just one click away during set up with the near field communication feature on the system. Additionally, Smith+Nephew provides 24-hour customer support for patients and a clinical hotline.   
 
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. Its 18,000 employees help develop and manufacture new technologies across three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in Hull, U.K., in 1856, the company now operates in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100. 

* based on Medicare beneficiaries
 
References 
¹ Smith+Nephew 2022. Internal Report. EO.AWM.PCS270.003.v1.
² Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care. 2014 Mar;37(3):651-8. Numbers are rounded where appropriate.
³ Sen CK. Human wounds and its burden: An updated compendium of estimates. Advances in Wound Care, 2019; 8(2):39-48 
⁴ Phillips T, StantonB, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol. 1994;31(1):49–53
⁵ Smith and Nephew 2022. RENASYS EDGE System Human Factors Summative Report Summary. Internal Report. CSD.AWM.22.071.